More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... in clinical trials that could be the booster shot the stock needs to generate a rebound.

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...

A dose of the new Moderna spikevax autumn Covid booster vaccination before it is ... More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.